Spyre Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Spyre Therapeutics, Inc. (SYRE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On October 5, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company
Spyre Therapeutics (Nasdaq: SYRE) priced a $350M public offering of 4.1M shares at $85 each, with an option for $52.5M more. Proceeds will fund clinical trials, manufacturing, and R&D. The offering is expected to close Oct 7, 2026.
Spyre Therapeutics' CLO, Heidy King-Jones, sold 28,933 shares for $2.63M and exercised options for 28,933 shares at $14.50 each. The stock has risen 487% in a year but is deemed overvalued. Spyre's market cap is $7.93B. Recent Phase II trial results showed mixed efficacy for its rheumatoid arthritis treatment, with analysts maintaining Buy/Outperform ratings and price targets between $110 and $130.
Over the past 7 days, AlphAI's AI scored 15 news stories mentioning SYRE (Spyre Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 15 bearish.
Recent SYRE coverage spans financial news, insider activity and corporate actions.
In the last 30 days, SYRE insiders filed 17 SEC Form 4 transactions — no purchases and 17 sales ($6.3M). The most active reporter was Turtle Cameron, Chief Executive Officer, with 6 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The large equity raise will likely dilute existing shareholders and put downward pressure on the stock.
The capital raise provides cash for R&D but introduces dilution, likely creating modest downward pressure on the stock.
The insider sale may create short‑term selling pressure.
Potential short‑term downside as insider sells signal reduced confidence.
The insider sale may signal reduced confidence and could weigh on the stock.
AlphAI scores every news story that mentions SYRE with an AI model for sentiment and relevance, and aggregates insider trades from Spyre Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Spyre Therapeutics, Inc. (SYRE) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement On October 5, 2026, Spyre Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company
2 min readSpyre Therapeutics (Nasdaq: SYRE) priced a $350M public offering of 4.1M shares at $85 each, with an option for $52.5M more. Proceeds will fund clinical trials, manufacturing, and R&D. The offering is expected to close Oct 7, 2026.
2 min readSpyre Therapeutics' CLO, Heidy King-Jones, sold 28,933 shares for $2.63M and exercised options for 28,933 shares at $14.50 each. The stock has risen 487% in a year but is deemed overvalued. Spyre's market cap is $7.93B. Recent Phase II trial results showed mixed efficacy for its rheumatoid arthritis treatment, with analysts maintaining Buy/Outperform ratings and price targets between $110 and $130.
2 min readSpyre Therapeutics CFO Scott Burrows sold 25,000 shares for $2.26M in early October 2026, following stock option exercises. Shares were sold at prices ranging from $89.00 to $93.59. The company's stock has surged 486% over the past year, but is considered overvalued. Recent clinical trial results were mixed, with analysts offering varied ratings and price targets, including Buy ratings from Guggenheim, Stifel, and JPMorgan.
2 min readSpyre Therapeutics CEO Cameron Turtle sold 14,000 shares ($1.38m) of SYRE stock on October 1, 2026, under a 10b5-1 plan. He retains 537,540 shares. SYRE's stock surged 487% in the past year but is deemed overvalued. Recent Phase II trial results showed mixed efficacy, leading to a stock decline. Analysts maintain Buy ratings with targets ranging from $110 to $130.
1 min readKing-Jones Heidy (See Remarks) sold 28,933 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $91.03 ($89.24–$93.46, $2.63M total) across 5 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readTurtle Cameron (Chief Executive Officer) sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $92.01 ($89.14–$93.91, $1.38M total) across 6 trades on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readBurrows Scott L (Chief Financial Officer) sold 25,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $90.47 ($89.07–$93.57, $2.26M total) across 6 trades over 2026-09-30 to 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readParadigm BioCapital Advisors LP and related entities reported a 5.1% stake in Spyre Therapeutics (SYRE), owning 4,457,450 shares as of September 24, 2026. The Fund also owns 3,928,646 shares (4.5%). The percentages are based on 88,173,762 shares outstanding as of July 28, 2026.
1 min readBTIG reaffirmed its Buy rating on Spyre Therapeutics, setting a $121 price target, implying a 35.9% upside from its Sep 30 close of $89.03. The firm highlights the company's strong market potential in IBD and other immune-mediated conditions, with a promising pipeline and favorable safety profile.
2 min read
